Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 15/20 | 0.42 |
| ▸ | HSD11B2 | P80365 | 2/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 3/20 | 0.34 |
| ▸ | JAK1 | P23458 | 3/20 | 0.34 |
| ▸ | TYK2 | P29597 | 3/20 | 0.34 |
| ▸ | JAK3 | P52333 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12791827 | 0.83 | HSD11B1 (0.44) | HSD11B1HSD11B2EPHX2 | |
| SCHEMBL2636721 | 0.83 | HSD11B1 (0.44) | HSD11B1HSD11B2EPHX2 | |
| SCHEMBL8099017 | 0.81 | HSD11B1 (0.44) | HSD11B1HSD11B2EPHX2 | |
| SCHEMBL13081509 | 0.77 | HSD11B1 (0.44) | HSD11B1HSD11B2EPHX2 | |
| SCHEMBL10087714 | 0.77 | HSD11B1 (0.40) | HSD11B1HSD11B2EPHX2 | |
| SCHEMBL13586952 | 0.77 | HSD11B1 (0.41) | HSD11B1HSD11B2EPHX2JAK2 | |
| SCHEMBL3042143 | 0.77 | JAK2 (0.40) | HSD11B1JAK2JAK1JAK3 | |
| SCHEMBL3218526 | 0.76 | HSD11B1 (0.41) | HSD11B1HSD11B2EPHX2 | |
| SCHEMBL1155595 | 0.76 | HSD11B1 (0.50) | HSD11B1EPHX2 | |
| SCHEMBL12128673 | 0.75 | HSD11B1 (0.46) | HSD11B1HSD11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216798-A1 | FUSED HETEROCYCLES AS LCK INHIBITORS | ASTELLAS PHARMA INC (JP) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216798-A1 | FUSED HETEROCYCLES AS LCK INHIBITORS | LCK, ZAP70, FYN | HSD11B1 3157/4885HSD11B2 3682/4885EPHX2 2243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.